Clinical Trial Update: Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 [Phase 2]

View source ↗

Summary

Phase 2 trial assessing GS-4997 alone or with simtuzumab in adults with NASH and fibrosis (F2-F3); study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis
• Non-alcoholic Steatohepatitis

Drugs mentioned

• GS-4997
• Simtuzumab (simtuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2019-06-26